Although EGFR tyrosine kinase inhibitors (TKIs) are clinically used to treat NSCLC, their acquired resistance driven by EGFR mutations remains a major driver of malignant progression [35]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.